Sorrento's R&D yakatarisana nekutyaira hunyanzvi muCCIDID-19, kurapwa kenza, kudzora marwadzo akazara uye autoimmune zvirwere.

Zvirongwa zvinokosha	Chiratidzo	Preclinical	Phase I	Phase II	Chikamu III/Chinokosha	FDA Chibvumirano
COVID-19 Zvirongwa
COVISTIX™ (diagnostic) Rapid Antigen Test 0%* Emergency Use Authorization (EUA) muMexico (COFEPRIS), Brazil (ANVISA), uye CE Yakanyorwa muEurope. COVIMARK™ (diagnostic) Rapid Antigen Test 0%* Chikumbiro chakatumirwa muUS neCanada cheEmergency Use Authorization (EUA) VIREX (diagnostic) Kumba Diagnostic 60.2%* EUA Enabling Studies in Q3 2022 OQORY™ (COVI-MSC) ARDS nekuda kweCOVID-19 muICU Varwere 82%* Muedzo Wakakosha muBrazil                           OVYDSO (Olgotrelvir) Anti-hutachiona (Piritsi remuromo) 40%* Omicron mRNA Vaccine mushonga 20%*
Zvirongwa zvinokosha	Chiratidzo	Preclinical	Phase I	Phase II	Chikamu III/Chinokosha	FDA Chibvumirano
immunotherapy
FUJOVEE™ (Abivertinib) NSCLC 82%* FUJOVEE™ (Abivertinib) B Cell Lymphomas 60.2%* FUJOVEE™ (Abivertinib) Prostate 20%* PD-L1 (Socazolimab)* SCLC 82%* *Mukubatana naLee's Pharm muChina PD-L1 (STI-3031)** Cervical Cancer 82%* ** MuUS uye mukubatana neImmuneOncia muKorea CD47 Solor Tumors 40%* CD38 DAR-T Multiel Myeloma 40%* CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, uye esophageal 40%* TROP2 ADC* Solor Tumors 40%* Seprehvec™ oncolytic virus Solid Tumors; CNS Tumors 40%* BCMA ADC Liquid Tumors 20%* Bevacizumab-ADAB™ Endometrial Cancer 40%* Mukubatana neMayo Clinic Bevacizumab-ADAB™ Ovarian Cancer 40%* Mukubatana neMayo Clinic Rituximab-ADAB™ B-cell Lymphomas 40%* Mukubatana neMayo Clinic Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL), Melanoma 40%*
Zvirongwa zvinokosha	Chiratidzo	Preclinical	Phase I	Phase II	Chikamu III/Chinokosha	FDA Chibvumirano
Pain
ZTlido® 1.8% Postherpetic Neuralgia - PHN 99.8%* Gloperba® Kurapa Gout (Oral) 99.8%* SEMEXA (SP-102) Lumbar Radicular / Sciatica Pain 82%* SP-103 (Lidocaine Topical System 5.4%) Acute Back Kurwadziwa 60.2%* SP-104 (Yanonoka Kuputika Yakaderera Dose Naltrexone) Fibromyalgia 20%* RTX (resiniferatoxin) Epidural injection Marwadzo Asingagoneki muAdvanced Cancer 60.3%* Nherera zita RTX (resiniferatoxin) Intra-articular nzira Marwadzo ari pakati nepakati kusvika Pamabvi Akanyanya OA 60.2%*
Zvirongwa zvinokosha	Chiratidzo	Preclinical	Phase I	Phase II	Chikamu III/Chinokosha	FDA Chibvumirano
Lymphatic Drug Delivery
Sofusa® anti-TNF Autoimmune (RA) 40%* Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL), Melanoma 40%* Sofusa® anti-CTLA-4 Melanoma 40%* Mukubatana neMayo Clinic

COVID-19 Zvirongwa
Zvirongwa zvinokosha (Chiratidzo)	Phase
COVISTIX™ (diagnostic) FDA EUA COVIMARK™ (diagnostic) FDA EUA VIREX (diagnostic) PH III FUJOVEE™ (Abivertinib) Ph III OQORY™ (COVI-MSC) Ph III OVYDSO (Olgotrelvir) Ph II Omicron mRNA Vaccine Preclinical

immunotherapy
Zvirongwa zvinokosha (Chiratidzo)	Phase
FUJOVEE™ (Abivertinib) Ph III FUJOVEE™ (Abivertinib) Ph II FUJOVEE™ (Abivertinib) Preclinical PD-L1 (Socazolimab)* Ph III PD-L1 (STI-3031)** Ph III CD47 (Mamota Akasimba) Ph I CD38 DAR-T (Multiple Myeloma) Ph I CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, uye esophageal) Ph I TROP2 ADC* (Mamota Akasimba) Ph I Seprehvec™ oncolytic virus (Mamota Akasimba; CNS Tumors) PH I BCMA ADC (Liquid Tumors) Preclinical Bevacizumab-ADAB™ (Endometrial Cancer) Ph I Bevacizumab-ADAB™ (Ovarian Cancer) Ph I Rituximab-ADAB™ (B-cell Lymphomas) Ph I Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I

Pain
Zvirongwa zvinokosha (Chiratidzo)	Phase
ZTlido® 1.8% (Postherpetic Neuralgia - PHN) FDA Chibvumirano Gloperba® 1.8% Kurapa Gout (Oral) FDA Chibvumirano SEMEXA (SP-102) Ph III SP-103 (Lidocaine Topical System 5.4%) Ph II SP-104 (Yanonoka Kuputika Yakaderera Dose Naltrexone) Preclinical RTX (resiniferatoxin) Epidural injection Ph II RTX (resiniferatoxin) Intra-articular nzira Ph II

Lymphatic Delivery
Zvirongwa zvinokosha (Chiratidzo)	Phase II
Sofusa® anti-TNF (Autoimmune RA) Ph I Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I Sofusa® anti-CTLA-4 (Melanoma) Ph I